Background: Sclerosis in the sacroiliac joints (SIJ) on radiography and computed tomography (CT) is common but widely considered a non-specific finding of sacroiliitis due to an association with degeneration and osteitis condensans ilii, despite little formal study. Availability of low dose radiation CT may lead to more widespread use for diagnostic evaluation. Objectives: We standardized the definition of sclerosis on CT and then aimed to determine whether this lesion could be reliably detected and its diagnostic utility. Methods: 215 CT scans were obtained from patients with a history of low back pain. 107 patients had a clinical diagnosis of spondyloarthritis (SpA) and 108 patients were clinically proven not to have SpA. Groups were age and gender matched (140 males, 75 females, mean age was 45 years). Three musculoskeletal radiologists, blinded to patient demographics and diagnosis, scored the CTs after standardization of lesion definitions and calibration. Erosions, sclerosis, and ankylosis were graded by size and number of articular surfaces/ joints involved. Sclerosis was considered definite if located along the cartilaginous compartment, measured >5mm in all 3 planes, and present >5mm from the joint surface. Discrepant scores were arbitrated and inter-reader reliability calculated by intra-class correlation coefficient (ICC). Diagnostic utility of CT lesions was determined by calculating sensitivity and specificity for the clinical diagnosis and by logistic regression. Results: ICC for sclerosis and erosion for each articular surface ranged from 0.65-0.76 and 0.71-0.78, respectively. ICC for ankylosis was 0.87-0.89. Sclerosis occurred in 87 (81%) cases with SpA and 25 (23%) controls. For a single articular surface the specificity for sacroiliitis ranged between 88-94%, for any two articular surfaces 95-100%, for all 4 articular surfaces 100%. Sensitivity ranged from 14% (4 articular surfaces) to 55% (either ilium). Erosion and ankylosis had a similar specificity range of 91-100% and 92-93%. The odds ratio was 4.9 for presence of definite sclerosis, and 12.6 for bilateral joint involvement. The odds ratio increased to 84.2 for bilateral erosion and 22.8 for bilateral ankylosis. Conclusions: When sclerosis measures >5mm in three planes and is located >5mm from a joint perimeter, it has high specificity for sacroiliitis, regardless of how many articular surfaces are involved, with similar specificity to erosion and ankylosis. Background: There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA) 1 was developed and validated. Identification of factors that predict long-term mMDA response in pSpA patients (pts) can facilitate decisions regarding treatment initiation and maintenance. Objectives: The purpose of this analysis was to determine predictors of long-term mMDA response following adalimumab (ADA) treatment in pSpA pts from the ABILITY-2 study. Methods: ABILITY-2 2 was a phase 3 randomized, double-blind trial evaluating the efficacy and safety of 40 mg ADA every other week versus placebo (PBO) over 12 weeks (wks) followed by open-label (OL) ADA for 144 wks in pts with pSpA. This post-hoc analysis included pts who received at least one dose of ADA during the PBO-controlled period or OL extension. The mMDA for pSpA was defined as achieving at least 5 out of the following 6 criteria: 1) TJC78 ≤1; 2) SJC76 ≤1; 3) pt pain visual analog scale (VAS) ≤15 of 100 mm; 4) pt global activity
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Background: There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA) 1 was developed and validated. Identification of factors that predict long-term mMDA response in pSpA patients (pts) can facilitate decisions regarding treatment initiation and maintenance. Objectives: The purpose of this analysis was to determine predictors of long-term mMDA response following adalimumab (ADA) treatment in pSpA pts from the ABILITY-2 study. Methods: ABILITY-2 2 was a phase 3 randomized, double-blind trial evaluating the efficacy and safety of 40 mg ADA every other week versus placebo (PBO) over 12 weeks (wks) followed by open-label (OL) ADA for 144 wks in pts with pSpA. This post-hoc analysis included pts who received at least one dose of ADA during the PBO-controlled period or OL extension. The mMDA for pSpA was defined as achieving at least 5 out of the following 6 criteria: 1) TJC78 ≤1; 2) SJC76 ≤1; 3) pt pain visual analog scale (VAS) ≤15 of 100 mm; 4) pt global activity In pSpA pts treated with ADA, mMDA (5/6 LEI or SPARCC) was achieved by almost 41%, 49%, and 50% of pts at yrs 1, 2, and 3, respectively and sustained mMDA response was achieved by 42% of pts. Regardless of mMDA definition, achieving mMDA response at wk 16 (up to 16 wks of ADA) was a robust positive predictor of attaining both long-term mMDA at yrs 1-3 and sustained mMDA (Figure) . In the model examining the BL predictors (model without mMDA16), age, BL enthesitis and BL BASDAI scores were most commonly selected as negative predictors for achieving long-term and sustained mMDA. Other selected predictors included BL dactylitis, physician's global assessment, hsCRP, and male sex; however, these predictors were not consistently selected for all time points or sustained mMDA. Conclusions: Early mMDA response is a stronger and more consistent predictor of long-term mMDA, whether at 1, 2, or 3 yrs or sustained over time, than BL
